Resources

Resources & News

No Results Found

Try adjusting your search to find what you’re looking for.

Research: Lab improves management of FBS

case-studies
Jan 09, 2023
US-based research laboratory, at a leading cancer research institution, struggled with the variability typically associated with FBS lots from their suppliers, which created risk and extra work for the lab’s personnel as they worked to optimize cell proliferation.

Cell Therapy: Assurance of supply when scaling

case-studies
Feb 09, 2023
US-based clinical stage Cell Therapy company focused on allogeneic platform needed to secure supply for Yssel’s T-Cell media to confidently meet their manufacturing scale up following positive results from their clinical development process.

Gene Therapy:  Scaling from lab to cGMP

case-studies
Feb 09, 2023
US-based, pre-clinical stage Gene Therapy innovator scaling products from benchtop to pilot required a nimble liquid manufacturing partner to rapidly manufacture and adjust buffers for process optimization.

Research: Lab requires AOF components

case-studies
Feb 10, 2023
Southern US-based cell therapy research lab, located at world renowned cancer research institution, investigating the use of genetically modified CAR NK cells was experiencing inconsistent cell biological activity due to IL-2.

Cell Therapy: Simplified liquid manufacturing

case-studies
Feb 10, 2023
Southeast Asian clinical stage Cell Therapy company focused on allogeneic cell therapies required custom aliquots of media components, including human serum, cytokines, growth factors, and other components in single use containment bags to simplify their workflow.

Cell Therapy: Regulatory compliant human AB serum

case-studies
Feb 11, 2023
Middle Eastern-based, clinical stage Cell Therapy company needed to reduce risk and potential concerns from the US FDA regarding cell culture products with animal components.

BioPharma: Improved workflow via collaboration

case-studies
Feb 12, 2023
US-based $1B market cap biotechnology company focused on therapeutic antibodies lacked the internal cGMP liquid manufacturing capabilities to support their projects once they reach pilot scale, and required nimble partner to rapidly manufacture and adjust buffers for process optimization.